Blencowe Resources: Aspiring to become one of the largest graphite producers in the world. Watch the video here.
According to the ASU, Mologic's lateral flow antigen test has to be analysed in a lab setting, very strange if true. Either way, their test will be ready for commercial sales at the end of the year/ start of next. We are already producing the test with BBI. Just waiting on data from CONDOR. Looking at the CONDOR timelines for other lateral flow assays (albeit antibody lateral flow) data should be ready within the next week. Info on Avacta and Mologic LFT can be found at https://chs.asu.edu/diagnostics-commons/testing-commons
MR.Spacetomato- I'm an investor in Avacta- you've read my post incorrectly. I'm saying they only have CE marking for the first and the antigen test is three months away from commercial sales. I would expect this test to be ready to sell in a month
Expecting commercial sales of AVCT test within the next month, validation should be complete within a week and CONDOR will accelerate CE marking ect. whilst BBI are already manufacturing.
Contract manufacturing arrangement for four Mologic tests:
– Mologic COVID-19 lab-based ELISA antibody test
– Mologic COVID-19 lab-based ELISA antigen test
– Mologic lateral flow antigen test
– Mologic lateral flow antibody test
The first is CE marked and we’ve shipped our first orders, with evaluations being undertaken in 15 countries. The others are in the process of technical transfer and will then gain CE marking – looking at being ready for commercial sales in Sept (Mologic lateral flow antibody test), October / November (Mologic COVID-19 lab-based ELISA antigen test) and a further two months later (Mologic lateral flow antigen test).
The Abbott rapid test is much-needed by the US step and will reduce the spread of CV19
It has limitations:
1. Can only be ordered by a physician, only be used in a clinical setting and by a clinician at that, limiting its ease of use
2. Test is by nasopharyngeal swab- if you've had a CV19 test in the UK, you know it's not pleasant
3. No over-the-counter/ home-use approval -again major limitation
4. S/s values are in thev. good range, as you'd expect for symptomatic individuals
5. No data published for asymptomatic cases- I would expect this to be lower for most rapid antigen-based tests, however good. In actual fact, even if the sensitivity data for this test was 80% for asymptomatic, would still be good. The fact they haven't published this data is a major red flag.
Having said that all their tests until at least December are for the US, who will almost certainly still require further testing capacity. A way to increase detection in asymptomatic would be to run two different inexpesive rapid tests in parallel, so we could also be of use in this scenario
Agreed re. data collection.
Hoping the route to doing this is distinctly alternative- treatment of individuals with SNG001 with their consent, where SNG001 is touted as an experimental drug, to bolster numbers.
Will be revealed shortly either way
As yu said it's phase II, because of numbers (100). My thinking is the second phase of the trial, should it be successful, would bolster numbers nearer to phase III. The goal of phase III is to determine a drug's therapeutic effect, which they they seem to have determiend
Is flawed as is the writer's lack of understanding of the scientific process and emergency approval. Although 100 individuals is a smallish study, it's enough to show efficacy of a drug and was the study not in fact phase II/phase III? I'm expecting publication of the entire set of COVID19 data in a good journal shortly, in addition to the COPD results. Was lucky enough to invest in Synairgen a few days before the rise because of the publication showing complete depletion of interfeon beta in severely affected COVID19 individuals.
Impaired type I interferon activity and inflammatory responses in severe COVID-19 patients by Hadjadj et al
Other publications have also found depletion or impaired production in COVID.
https://www.delisted.com.au/company/battle-mountain-gold-company
According to the above link Battle Mountain is a subsidiary of Newmont and became so in 2001
https://leafyquick.com/collections/cbd-oil
They have the most reviews, all 5* and are the first product on the webpage. Will be huge, once they start selling the seed. Hemp is now seen as a much more durable, sustainable alternative to cotton and grows three times as quickle. There are multiple uses for it. Hemp isn't cannabis, people have to be made aware of this.
Also Nick Tullock seems very quick off the mark and a doer, was the managing director for Corporate Finance at Cantor. Much rather he at the helm of this company.